Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

scientific article published on June 20, 2003

Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 159 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 159 Warning: foreach() argument must be of type array|object, null given in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 161
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.11074
P953full work available at URLhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fijc.11074
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.11074
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.11074
P698PubMed publication ID12704675
P5875ResearchGate publication ID7466936

P50authorFritz H. SchröderQ24517867
Harry J de KoningQ86770830
P2093author name stringIda J. Korfage
Ingrid W. van der Cruijsen
Suzie J. Otto
Jan J. Lous
Michael K. Liem
P2860cites workDevelopment of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological ResearchQ38478798
Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.Q38490622
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trialQ39486360
Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).Q39512571
Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examinationQ39556871
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaQ39579022
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trialQ39589717
Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands, 1971–1995Q50159463
International trends in prostate-cancer mortality in the "PSA ERA".Q50674659
Rationale for randomised trials of prostate cancer screeningQ59830999
Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trialQ61881631
PSA-use in a Spanish industrial areaQ74325636
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectoncologyQ162555
P304page(s)394-399
P577publication date2003-06-01
2003-06-20
P1433published inInternational Journal of CancerQ332492
P1476titleEffective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
P478volume105

Reverse relations

cites work (P2860)
Q37184507Algorithms, nomograms and the detection of indolent prostate cancer
Q34010805Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition
Q33781171Assessing the amount of unscheduled screening ("contamination") in the control arm of the UK "Age" Trial
Q37806834Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial?
Q44740163Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer
Q51019661Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening
Q30878080Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data
Q48367260Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.
Q76382506European Randomized Study of Screening for Prostate Cancer: achievements and presentation
Q39180719Impact of cause of death adjudication on the results of the European prostate cancer screening trial.
Q45131359Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
Q43743647Intake of whole-grain products and risk of prostate cancer among men in the Danish Diet, Cancer and Health cohort study
Q45216796Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
Q37389162Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group.
Q37457676Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
Q36103672Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales
Q36013544Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC.
Q44328071Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007.
Q26781093Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis
Q41849568Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum
Q34261229Prostate-cancer mortality at 11 years of follow-up
Q37430370Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives
Q47123251Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate
Q37963657Risk-based prostate cancer screening.
Q24201690Screening for prostate cancer
Q24245476Screening for prostate cancer
Q75422425Screening for prostate cancer: have you had your cholesterol measured?
Q34383106Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trial
Q47358352The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
Q37777325The implementation of screening for prostate cancer
Q35675436The story of the European Randomized Study of Screening for Prostate Cancer

Search more.